Individualized Vaccine Development for Infectious Diseases

Md Mostafizur Rahman [1*], Md Abu Bakar Siddique [1], Moushumi Afroza Mou [1], Amatun Noor Prapty [1]

Abstract

Vaccination has significantly enhanced global health, improving the quality of life for humans and animals, reducing treatment costs, and saving countless lives. Traditional vaccines were developed empirically, often with limited understanding of their effects on the human immune system. However, several challenges have emerged, including concerns about immunological safety, the need for individualized vaccines, and issues related to pathogens with complex lifecycles and antigenic variability. These concerns highlight risks such as non-antigen-specific immune responses, which may lead to autoimmunity or vaccine allergies. To address these challenges, immunologists are exploring innovative approaches to vaccine design. Immunoinformatics has become a transformative tool, enabling a deeper understanding of viral pathophysiology, immune responses, computational vaccinology, and diagnostics. The role of immunoinformatics in infectious disease research depends on the computational methods applied, particularly those that analyze host-pathogen interactions. Additionally, bioinformatics techniques are being leveraged to identify gene targets for vaccine development, including integrating pregnant women into vaccine trials and programs more effectively. This review emphasizes the critical need for advancing experimental, computational, and hybrid approaches to study host-pathogen interactions and drive innovations in vaccine development.

Keywords: Immunoinformatics, Computational Vaccinology, Vaccine Design, Emerging Infections, Immune System.

Significance | Personalized vaccines offer a promising solution for enhancing immunization efficacy, overcoming pathogen variability, and addressing diverse population health needs.

*Correspondence. Md Mostafizur Rahman, Department of Biological Sciences, St. John's University, New York, United states.

Editor Md Shamsuddin sultan khan And accepted by the Editorial Board April 28, 2020 (received for review February 14, 2020)

Introduction

Vaccination remains one of the most successful public health initiatives for preventing infectious diseases worldwide. Over the past decade, the concepts of vaccinomics and adversomics have emerged as groundbreaking frameworks, grounded in the immune response network theory (Urrutia-Baca et al., 2019). These approaches integrate immunogenomics, systems biology, and immunogenetics to unravel the mechanisms behind individual variations in vaccine-induced immune responses and the occurrence of adverse effects (Manzoni et al., 2018). By exploring both genetic and non-genetic factors, vaccinomics and adversomics provide a deeper understanding of how populations and individuals respond to vaccines.

Central to these fields is the application of high-throughput, high-dimensional systems biology techniques to predict protective and maladaptive immune responses to vaccines (Poland et al., 2016). This predictive and personalized vaccinology approach evaluates factors such as genetic background, sex, and other variables influencing vaccine immunogenicity, efficacy, and safety (Peng et al., 2019). The integration of these principles into vaccine development represents a paradigm shift, moving from traditional empirical methods to a knowledge-driven model for designing safer and more effective vaccines.

Our research and others' work have demonstrated how vaccinomics — through its use of immunogenetics and immunogenomics — can guide the development of novel vaccine

Author Affiliation.
[1] Department of Biological Sciences, St. John's University, New York, United states.

Please Cite This:
Rahman, M. M., Siddique, M. A. B., Mou, M. A., Prapty, A. N. (2020). "Individualized Vaccine Development for Infectious Diseases", Journal of Precision Biosciences, 2(1),1-10,2024

candidates (Wallis et al., 2019). By applying these principles, predictive immunological signatures of vaccine responses can be identified, quantified, and explained. We have also introduced an initial mathematical model and prediction equation to characterize the non-random processes underlying immune responses to vaccines (Ali et al., 2019). While this equation is still in its infancy and cannot yet fully predict immune responses, it represents an essential first step toward a more systematic and informed approach to vaccine development.

Traditional vaccine development methods, which rely on empirical strategies, have historically been misaligned with the principles of vaccinomics and adversomics. These conventional approaches often struggle with complex diseases that possess intricate immune escape mechanisms, compounded by society's heightened safety expectations and declining vaccination rates. Moreover, the "one-size-fits-all" approach fails to account for the diversity and complexity of the human immune system and genetic makeup.

The promise of vaccinomics lies in its potential to identify immune response profiles, immunosignatures, and biomarkers that predict vaccine safety and efficacy. These insights could pave the way for the development of tailored vaccine candidates that address the challenges of emerging and reemerging infectious diseases while meeting the unique needs of individuals and populations.

2.Vaccine Immunology and Design

Producing vaccine-induced immunity is a complex and challenging process in immunology. The current generation of conventional vaccines was developed empirically, at a time when the mechanisms of immune system activation were poorly understood. Despite numerous studies attempting to address this complexity (Kim et al., 2019), the inherent challenges call for alternative approaches to vaccine development (Wallis et al., 2019). Immunoinformatics has emerged as a promising field, providing a systematic framework that considers various factors influencing vaccine design, such as pathogen antigenic variability, the formation of infectious diseases, and human genetic diversity (Figure 1).

One critical aspect of vaccine-induced immunity is the induction of immunological memory, which is essential for long-term vaccine efficacy. The intensity of this induction determines the effectiveness of the vaccine (Sarkander et al., 2016). Key factors include the persistence of antibodies, the number and type of immune memory cells produced, and the activation of immunological memory over time. Table 1 summarizes the primary immune effectors triggered by vaccines, with antibodies from B lymphocytes serving as the principal mediators (Giacomet et al., 2018). CD4+ and CD8+ T cells act as secondary effectors, binding to specific toxins or pathogens and playing a vital role in immune responses.

Both cell-mediated and humoral immune responses are elicited by vaccines and antigens (Munang'andu et al., 2015). Vaccines that leverage both B and T cell responses have demonstrated greater efficacy. While B cells are the primary immune effectors, T cells stimulate the production of high-affinity antibodies and memory cells, which are critical for long-term immunity. Studies utilizing immunomics and reverse vaccinology have identified novel vaccine targets using tools like EpiMatrix, demonstrating that T cells can serve as the dominant immune effectors (Davies et al., 2015). This shift in focus has led to significant advancements in vaccine design.

2.1 Addressing Challenges in Vaccine Design

Despite advancements in vaccine development, significant challenges remain, particularly for vulnerable populations such as the elderly, young children, and immunocompromised individuals (Simon et al., 2015). These populations often exhibit diminished immune responses, necessitating a deeper understanding of how vaccines perform in these groups. For instance, polysaccharide antigens, also known as type II T-cell-independent (TI-2) antigens, can induce persistent humoral immunity without generating memory B cells. While these antigens elicit long-lasting immunity, their lack of recall responses can limit vaccine efficacy (Palm et al., 2019). In contrast, protein and DNA antigens induce both memory B cells and sustained immunity, highlighting the importance of targeting the appropriate antigens to optimize vaccine performance.

Conventional approaches to vaccine development often rely on cloning and expressing major surface antigens of pathogens. However, this method has frequently resulted in vaccines with poor immunogenicity that require strong adjuvants to elicit adequate immune responses (Burton et al., 2017). This approach is particularly ineffective against pathogens with highly variable antigens, such as RNA viruses, or those with complex life cycles, such as parasites. Enhancing vaccine specificity to address unique pathogen features, rather than merely increasing vaccine efficacy, is critical for addressing these challenges (Rauch et al., 2018).

2.2 Advances in Neglected Tropical Diseases and Pathogen Genomics

Efforts to develop vaccines for neglected tropical diseases (NTDs) have gained momentum due to the initiatives of pharmaceutical companies and global health organizations, which have prioritized research on diseases affecting developing nations (Hotez et al., 2013). Vaccines for several NTDs are currently in various stages of development (Paul et al., 2019). A critical advancement has been the availability of pathogen genomes through international research collaborations, allowing computational vaccinology to identify potential vaccine targets (Nii-Trebi et al., 2017). These technologies enable the screening of pathogenic genomes to identify proteins associated with virulence and model key genes for vaccine candidates specific to each pathogen.

Immunoinformatics offers a powerful toolset for analyzing these genomic datasets, facilitating the identification of antigens with

high immunogenic potential. By leveraging computational approaches, researchers can model protein structures, predict antigenic regions, and simulate immune responses. These methods have accelerated the development of vaccines tailored to specific pathogens, especially those with complex immune evasion strategies.

2.3 The Promise of Immunoinformatics

The application of immunoinformatics extends beyond vaccine development to personalized medicine. By accounting for individual genetic and immunological differences, immunoinformatics allows for the design of vaccines tailored to specific populations or even individuals. This is particularly relevant for emerging and reemerging infectious diseases (ERIDs), where antigen variability presents a significant challenge. Predictive models and computational tools can identify immunosignatures and biomarkers that indicate vaccine safety and efficacy, guiding the development of next-generation vaccines.

Moreover, immunoinformatics enables the integration of diverse data sources, such as host genetic variation, pathogen genomics, and immune system dynamics, to create a comprehensive understanding of host-pathogen interactions. This systems-level approach is essential for addressing diseases with complex pathogenesis and for developing vaccines with broad and long-lasting protection.

Traditional vaccine development approaches, though successful in the past, are increasingly inadequate for addressing the complexities of modern infectious diseases. Immunoinformatics provides a transformative framework for vaccine design, offering tools to address pathogen variability, optimize antigen selection, and tailor vaccines to specific populations. As genomic and computational technologies continue to advance, immunoinformatics holds the potential to revolutionize vaccine development, ensuring safer, more effective, and more personalized solutions for preventing infectious diseases.

3. Immunoinformatics and Infectious Disease

Immunoinformatics has emerged as a vital field in immunology, addressing the challenges of managing massive datasets generated by immunological research, pathogen-host interaction studies, and large-scale genomic and proteomic projects. This interdisciplinary field uses computational methods to analyze immune system function, integrating statistical, computational, mathematical, and biological knowledge (Hegde et al., 2018). It focuses on data collection, storage, and analysis, using tools such as database creation, structural and functional signature analysis, and predictive modeling to enhance our understanding of immune system dynamics (Table 2).

The immune system's complexity, combined with the variability of infections and environmental antigens, requires vast amounts of data to unravel its intricate pathways. Vertebrate immune systems involve multiregulatory pathways and highly virulent antigens, often making traditional research approaches insufficient. Immunoinformatics offers computational solutions to streamline vaccine design, making the process more precise and targeted. Techniques such as disease etiology analysis, immune system dynamics modeling, computational vaccinology, structural modeling, and motif analysis are critical for identifying vaccine candidates and understanding disease pathophysiology (Mills et al., 2015).

Computational vaccinology, a key application of immunoinformatics, has revolutionized vaccine research by identifying epitopes and predicting antigenic targets. By leveraging bioinformatics tools (Table 3), researchers can screen protein sequences, identify major histocompatibility complex (MHC) binding aggregates, and detect supertype motifs. These tools are instrumental in designing epitope-based vaccines tailored to genetically diverse human populations. For instance, computational models for bacterial, fungal, parasitic, and viral pathogens have been developed to analyze the complex mechanisms underlying infectious diseases (Utesch et al., 2018).

Incorporating immunoinformatics into infectious disease research has enhanced our ability to predict immune responses, design effective vaccines, and deepen our understanding of host-pathogen interactions. This integration has paved the way for innovative, data-driven approaches to combat emerging infectious diseases and improve global health outcomes.

4. Pathogens with Variable Antigens

Antigenic variability is a key mechanism used by pathogens to evade host immunity. Pathogen surface proteins are often highly diverse, enabling these organisms to escape immune detection. A successful infectious agent presents unique signals to the host immune system that differ from its pathogenic features. Many pathogens have evolved sophisticated strategies to avoid immune destruction. For instance, Toxoplasma invades host cells, evades phagocytosis, and disseminates throughout the host to establish infection (Delgado et al., 2019). While vertebrates possess robust immune defenses against foreign threats, pathogens have adapted to counteract these mechanisms, often outpacing immune effector responses.

"Antigenic variation" refers to a pathogen's ability to modify its surface proteins to avoid recognition by the host immune system. This process involves mechanisms such as phase variation, antigenic shifting and drifting, or structural modifications of antigenic proteins (Rash et al., 2017). Such variations are critical for microbial pathogenicity, allowing pathogens to evade adaptive immunity and re-establish infections. By altering their surface antigens, pathogens can bypass the host's immunological memory,

forcing the immune system to generate new immunoglobulins against the updated antigens.

Several bacteria, including Streptococcus species, Mycoplasma, Neisseria gonorrhoeae, and Neisseria meningitidis, exhibit significant antigenic variation (Harrison et al., 2017). Horizontal gene transfer, particularly through plasmid acquisition and bacteriophage-mediated transduction, plays a major role in antigenic variability. This process is often more impactful than point mutations, allowing non-virulent organisms to acquire virulence genes. Once equipped with such genes, these modified pathogens can rapidly proliferate and trigger new epidemics.

Understanding the mechanisms of antigenic variability is essential for combating infectious diseases, as it provides insights into how pathogens persist and evade host defenses, presenting significant challenges for vaccine development and disease management.

4.1 Pneumococcus

Streptococcus pneumoniae is a Gram-positive bacterium that poses a significant public health concern, causing diseases such as pneumonia, bacteremia, and otitis media. It is a major contributor to morbidity and mortality among both adults and children (Henriques-Normark, 2013). Currently, two types of vaccines are available to prevent pneumococcal infections: conjugate and polysaccharide vaccines. Conjugate vaccines enhance immunogenicity in children by attaching a non-pneumococcal protein to pneumococcal polysaccharides, while polysaccharide vaccines are primarily designed for adult use. However, the ability of these vaccines to provide comprehensive immunity against the pathogen remains uncertain.

One of the primary virulence factors of *S. pneumoniae* is its polysaccharide capsule, which forms the basis for its antigenic serotyping. Over 100 capsule types are known, but current vaccines only include antigens from the most prevalent serotypes in specific regions (Morais et al., 2018; Gilbert et al., 2015). A universal pneumococcal vaccine would require the identification of shared antigens among all serotypes. Advances in understanding the organism's DNA and strain diversity have opened new avenues for vaccine development.

4.2 Plasmodium

Plasmodium falciparum, the most virulent malaria-causing parasite, has two life cycles—one in humans and another in mosquitoes. The parasite expresses modified proteins such as Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) and Plasmodium falciparum hepatocyte membrane protein 1 (PfHMP1), which help it evade host immune defenses (Belachew et al., 2018). PfEMP1 proteins play a crucial role in cytoadherence, causing infected red blood cells to sequester in host tissues and evade spleen-mediated destruction (Hermand et al., 2018; Khoury et al., 2014).

PfEMP1 proteins are encoded by a family of var genes, with each *P. falciparum* haploid genome containing up to 50 var gene variants. This allows antigenic variation, as only one PfEMP1 protein is expressed at a time, preventing simultaneous recognition by the immune system (Jeppesen et al., 2015). Research has focused on understanding the binding properties of PfEMP1 and its role in infection severity, which could inform new vaccine strategies targeting this antigenic variation (Abdi et al., 2015; Bachmann et al., 2019).

4.3 Trypanosoma

Antigenic variability is a hallmark of many pathogens, including *Trypanosoma brucei*, the causative agent of African sleeping sickness. This eukaryotic parasite replicates in the host's bloodstream and later crosses the blood-brain barrier, causing severe neurological complications. To evade host immunity, *T. brucei* covers itself in a coat of variable surface glycoprotein (VSG), which prevents immune recognition (Schwede et al., 2015).

The genome of *T. brucei* contains over a thousand VSG genes, and only one is expressed at a time through genetic reassortments. This exclusive expression of VSG genes enables the parasite to evade humoral immunity, leading to recurrent infections and chronic disease. Some trypanosomes expressing atypical VSG genes can evade immune detection entirely, further complicating treatment efforts (Pinger et al., 2017). Understanding the mechanisms of VSG expression and antigenic variation is critical for developing targeted therapies.

4.4 Influenza Virus

Influenza is caused by RNA viruses classified into three types: A, B, and C. Vaccines for influenza currently target Types A and B and generate strong antibody responses to the surface glycoproteins hemagglutinin and neuraminidase. However, these vaccines are often ineffective against new viral strains due to antigenic drift and shift (Sautto et al., 2018).

Antigenic drift involves minor changes in viral antigens, while antigenic shift results in the emergence of a completely new virus subtype. These processes are primarily driven by changes in hemagglutinin and neuraminidase, which determine the virus's antigenicity. Host proteases cleave hemagglutinin into subunits, and the presence of lipophobic amino acids at the cleavage sites influences the virus's virulence (Hensley et al., 2011).

The surface glycoprotein hemagglutinin is a key target for immune responses and vaccine development. Immunoinformatics approaches can identify conserved regions within hemagglutinin, facilitating the design of universal vaccines capable of addressing antigenic drift and shift. This strategy holds promise for improving influenza control by providing broader and more durable protection.

5. Personalized Vaccination



Figure 1. Schematic illustration depicting the cases driving the need for an immunoinformatics-based approach in vaccine development.

Table 1. Functions of the Immunological Memories

Immune Cells	**Immunological Memories (Effectors of the Immune Response)**	**Mechanistic Functions**
B cells produced (humoral immunity)	Antibodies play vital roles in the control (including prevention) and complete removal or destruction of both extracellular and intracellular pathogens as well as in response to vaccination.	activate the complement cascade -neutralize the replicating power of viruses (viral infectivity) -prevent the diffusion of toxins and/or bind to their enzymatic active sites (comprising of the binding site and the catalytic site) -induction of the macrophages and neutrophils for the purpose of clearing extracellular bacteria
T-cell produced (cellular immunity)	T cells of the CD4+ class. Clears the pathogens residing within and outside the cells T cells of the CD8+ T class. Clear the pathogens residing in the cells	produces several interleukins and supports B-cell stimulation and differentiation (Th2 cells response) - produces Thi cell responses (produces interferon-y, tumor necrotic factor-/-B and Interleukins-2 and 3 and supports the proliferation and differentiation of CD8+T cells, B cells, and macrophages activate the B cells, cytotoxic T cells and other cells not involved in the immune system induces the release of antimicrobial cytokine for the purpose of killing microbial infected cells Kills infected cells directly by releasing proteolytic enzymes

Table 2. The Importance of Bioinformatics in the Research on Infectious Diseases

Importance	Applications
Surveillance of infectious disease	Microbial genotyping is used to eicher confirm or refute epidemiological links with potential environmental sources
Determining the various strains of pathogens in circulation	The proteins used by variants of pathogens can be predicted and mutated for better analysis. Even the genes that code for the proteins can be manipulated in silico in order to predictive.a better targeting
Diagnostic microbiology	Bio-surveillance focused text-mining tools and microbial profiling are used to detect infectious disease outbreak
Databases for Pathogens	Array of data on pathogens can help in their genome study and their virulence coward development of vaccine candidate
Vaccinology	Bioinformatics have helped in the advance of DNA and Epitope-based vaccines both in silico and as a preliminary study for the in vivo validation study

Table 3. potential epitopes for vaccine development

Bioinformatics Tools	Applications/Description
EpiMatrix	This is an in-silico product of EpiVax developed for predicting and identifying the immunogenicity of therapeutic proteins and epitopes. It is also used to re-design proteins and in designing T-cell vaccine
Conservacrix	Has been applied in comparing strings from different strains of same pathogens and for pathogens identification. Configuration of Conservatrix allows for amino acid replacement at unusual positions. Highly conserved T-cell epitopes in variable genomes such as some viruses are amenable to the algorithm
ClustiMer	Potential T-cell epitopes usually aggregate in specific immunogenic consensus sequence (ICS) regions as clusters of 9-25 amino acids with 4-40 binding motifs instead of randomly distribute throughout protein sequences. In combination with EpiMatrix, the ClustiMer algorithm may be used to identify those peptides with EpiMatrix immunogenicity cluster scores 2+10. Such peptides are usually immunogenic and tend to make a promising vaccine candidate.
BlastiMer	Using BlasciMer program, one may also choose to automatically BLAST "putative epitopes against the human sequence 55-57 database at GenBank". BLASTing screens off those epitopes with possible autoimmunity and cross reactivity questions and locates the epitopes that can safely be used in developing human or animal vaccine. BlastiMer can also BLASTs. sequences against PDB, SwissProt, PIR, PRF and non-redundant GenBank CDS translations
Vaccine CAD	This algorithm evaluates junctional epitopes for possible immunogenicity and inserts "spacers and breakers into the design of any string-of-beads construct".
NERVE	Predicts the best vaccine candidates starting from the flat file proteome of a prokaryotic pathogen. It's a fully automated reverse vaccinology system, developed to predict best VCs from bacteria proteomes and to manage and show data by user-friendly output
Jenner-Predict	Predicts PVCs from proteomes of bacterial pathogens. The web server targets host-pathogen interactions and pathogenesis 61 by considering known functional domains of protein classes such as adhesin, virulence, invasion, porin, flagellin etc
Vaxign	Is a vaccine target prediction and analysis system based on the principle

Personalized vaccination refers to designing vaccines tailored to maximize immunogenicity while minimizing adverse effects, reactogenicity, or vaccine failure. These vaccines are developed to address variations at individual, gender, racial, and subpopulation levels, offering targeted solutions to optimize immune responses.

5.1 Individual-Level Personalization

At the individual level, haplotype and polymorphism play critical roles in vaccine design. These genetic factors can either hinder the development of protective immunity or predict the likelihood of adverse vaccine reactions. Personalized vaccines consider such genetic variations to ensure efficacy and safety (Atsaves et al., 2019). For instance, immune response gene polymorphisms and their influence on vaccine-induced immunity are analyzed to identify adjuvants or formulations that overcome limitations caused by genetic differences (Piasecka et al., 2018).

A cornerstone of personalized vaccination is the understanding of T-cell recognition of pathogen-derived peptides within the major histocompatibility complex (MHC), also known as the human leukocyte antigen (HLA) system. HLA molecules exhibit stable polymorphisms and are well-characterized, making them ideal candidates for customization (Odimegwu et al., 2019). Despite their stability, HLA polymorphisms are highly complex. Over 12,000 alleles of HLA class I molecules and 4,000 alleles of class II molecules have been identified across human populations (Buhler et al., 2019).

HLA class I and II molecules have heterodimeric structures with highly variable extracellular domains (α1, α2, and β1), along with less variable transmembrane and cytoplasmic domains (Cruz et al., 2013). These molecules are encoded by eight exons, with exon 1 producing the leader peptide, exons 2–4 encoding the extracellular domains, and exons 6–8 contributing to the transmembrane anchor and cytoplasmic tail (Cruz et al., 2013). The variability within the α1 and α2 domains for class I molecules and the α1 and β1 domains for class II molecules accounts for the diverse antigen-binding properties of HLA molecules (Buhler et al., 2019).

5.2 Subpopulation-Level Personalization

In subpopulations, interactions between genetic, environmental, and host factors significantly influence vaccine responses. For example, specific medications may alter the transcription of immune response genes, impacting vaccine efficacy (Piasecka et al., 2018). Computational tools, such as peptide motif and MHC ligand prediction databases, aid in identifying binding patterns and anchor residues specific to each MHC molecule (Molineros et al., 2019). NetMHC prediction servers, for instance, are widely used to predict potential vaccine epitopes (Lundegaard et al., 2010).

An example of this approach is the study of the Lassa fever virus (LASSV). Sequencing analysis of its immunoproteome has identified the SSNLYKGVY peptide sequence (AA41-49 of glycoprotein 1) as an optimal epitope for vaccine development. This sequence, when combined with 17 HLA class I and 16 HLA class II molecules commonly found in large African populations, shows promise for designing a vaccine tailored to LASSV-endemic regions (Hossain et al., 2018). This methodology highlights the potential of personalized vaccination to combat emerging diseases.

5.3 Gender-Level Personalization

Gender-based differences in immune responses have also been observed. Research indicates that females generally exhibit stronger immune responses to vaccines than males. For example, females produce higher antibody titers against measles and rubella virus proteins, which may be influenced by hormonal and genetic factors (Fink et al., 2018; Fischinger et al., 2019). These variations underscore the importance of incorporating sex-specific data into vaccine design to optimize efficacy for both genders.

5.4 Vaccinomics and Its Role

Vaccinomics, the study of immune response gene polymorphisms and their effects on humoral, innate, and cell-mediated immunity, is integral to personalized vaccination. This field bridges immunogenomics and immunogenetics to understand population and individual-level immune responses to vaccines (Majumder et al., 2015).

The advent of vaccinomics was significantly influenced by the Human Genome Project and the International HapMap project, which provided insights into linkage disequilibrium maps and single nucleotide polymorphisms (SNPs). Modern molecular assay techniques, including high-throughput gene analysis, have further accelerated the development of personalized vaccines by identifying genetic markers associated with vaccine efficacy and adverse reactions.

5.5 Advances in Immunoinformatics

Immunoinformatics has emerged as a powerful tool for vaccine development. By analyzing pathogen immunoproteomes, researchers can predict T-cell and B-cell epitopes, binding sites, and target sequences. This approach enables the identification of conserved antigenic regions, facilitating the design of vaccines that are both specific and adaptable to diverse genetic profiles. For instance, immunoinformatics has been instrumental in identifying epitopes for pathogens like Lassa fever virus, providing a framework for developing targeted vaccines for specific populations (Hossain et al., 2018).

Personalized vaccination represents a paradigm shift in immunization, leveraging advancements in genetics, immunology, and computational biology to design vaccines tailored to individual and population-specific needs. By accounting for genetic polymorphisms, gender-based immune responses, and subpopulation-specific factors, personalized vaccines can maximize efficacy while minimizing adverse effects. As technologies like vaccinomics and immunoinformatics continue to evolve, the future of vaccination lies in precision medicine, offering hope for

combating emerging diseases and addressing global health disparities.

6. Challenges in Personalized Vaccinology

Despite the remarkable success of vaccines, vaccinologists continue to face numerous challenges. Developing effective vaccines against complex pathogens such as *Plasmodium* (malaria), *Mycobacterium tuberculosis*, HIV, rhinovirus, and hepatitis C virus, as well as emerging pathogens like the Zika virus (ZIKV), remains a significant hurdle. Complications arise from the aging and immunosenescent populations, insufficient understanding of neonatal immune systems, and growing numbers of immunocompromised individuals due to conditions like HIV, cancer, or medication-induced immunosuppression. Additionally, sex-based differences in vaccine responses and adverse event rates, coupled with increasing global rates of obesity and aging, further complicate vaccine development.

Vaccine safety has come under heightened scrutiny, exacerbated by the influence of anti-vaccine groups whose misinformation undermines public trust and reduces vaccine coverage rates ([96], [97], [98]). Vaccineomic approaches offer a promising pathway to address these challenges, providing insights to develop innovative strategies and novel vaccine candidates.

However, the full realization of personalized vaccines requires overcoming several critical obstacles:

Larger Genotype–Phenotype Datasets: High-quality datasets with thousands to tens of thousands of samples are needed to establish robust vaccine designs.

Integration of Diverse Data Types: High-throughput, high-dimensional data, including genomic, transcriptomic, and proteomic datasets, must be seamlessly integrated.

Reliable Biomarkers: Identifying biomarkers that predict individual responses or adverse reactions is essential for tailoring vaccine administration.

Shifting Correlates of Protection: Moving beyond humoral immunity as the primary correlate of protection is necessary. Cellular immune outcomes are expected to play a critical role in licensing future vaccines.

Advanced Analytical Approaches: Biostatistical and bioinformatics techniques capable of analyzing terabyte-scale, high-dimensional data are needed to identify causative networks and patterns.

Economic Barriers: Methods for technology transfer and funding are crucial to ensure novel vaccines reach low- and middle-income countries, which often face the highest burden of vaccine-preventable diseases, such as malaria.

The interplay of scientific, technological, and socioeconomic factors highlights the complexity of advancing personalized vaccinology. By addressing these challenges, the field can revolutionize global health and disease prevention.

7. Conclusion

The introduction of tailored vaccine development has revolutionized the field of disease prevention, marking a significant shift toward more precise and individualized healthcare. By accounting for the intricate interactions between genetics and immune responses, personalized vaccines hold immense promise in creating immunizations that are not only more effective but also customized to each individual's unique immune profile.

In the ongoing fight against infectious diseases, personalized vaccines offer a dynamic solution to address challenges posed by rapidly evolving pathogens. Their adaptability enables preventive measures to keep pace with the ever-changing nature of infections, providing a level of protection that traditional vaccines may struggle to achieve. Moreover, the personalized approach addresses concerns surrounding vaccine safety and efficacy by considering individual genetic predispositions, thus alleviating fears about side effects and dispelling skepticism around one-size-fits-all solutions. This patient-centered strategy fosters greater public trust in immunization programs while empowering individuals to take an active role in safeguarding their health.

While challenges related to ethics, cost, and scalability remain, the potential benefits of personalized vaccines underscore their transformative impact on global health. They promise a future where highly effective immunizations are tailored to the specific needs of each individual, paving the way for a healthier, more resilient world. As science and technology continue to advance, the era of personalized vaccines heralds a new frontier in disease prevention—one that prioritizes precision, adaptability, and the well-being of every individual.

Author contributions

M.M.R. conceptualized the study, supervised the research, and provided critical revisions to the manuscript. M.A.B.S. contributed to data collection, analysis, and interpretation. M.A.M. assisted in the design of the methodology and prepared the initial draft of the manuscript. A.N.P. contributed to data visualization and manuscript editing. All authors reviewed, revised, and approved the final version of the manuscript for submission.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Ali, S. A., Almofti, Y. A., & Abd-Elrahman, K. A. (2019). Immunoinformatics approach for multiepitopes vaccine prediction against glycoprotein B of avian infectious laryngotracheitis virus. Advances in Bioinformatics, 2019.

Anaya, J. M. (2013). Major histocompatibility complex: Antigen processing presentation: Chapter 10. In Autoimmunity. From Bench to Bedside (pp. 169-184). Universidad del Rosario.

Auladell, M., Jia, X., Hensen, L., Chua, B., Fox, A., Nguyen, T. H., ... & Kedzierska, K. (2019). Recalling the future: immunological memory toward unpredictable influenza viruses. Frontiers in immunology, 10, 1400.

Berical, A. C., Harris, D., Dela Cruz, C. S., & Possick, J. D. (2016). Pneumococcal vaccination strategies. An update and perspective. Annals of the American Thoracic Society, 13(6), 933-944.

Buhler, S., & Sanchez-Mazas, A. (2011). HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. PloS one, 6(2), e14643.

Chandra, H., & Yadav, J. S. (2016). Human leukocyte antigen (HLA)-binding epitopes dataset for the newly identified T-cell antigens of Mycobacterium immunogenum. Data in brief, 8, 1069-1071.

Collineau, L., Boerlin, P., Carson, C. A., Chapman, B., Fazil, A., Hetman, B., ... & Smith, B. A. (2019). Integrating whole-genome sequencing data into quantitative risk assessment of foodborne antimicrobial resistance: a review of opportunities and challenges. Frontiers in Microbiology, 10, 1107.

Crux, N. B., & Elahi, S. (2017). Human leukocyte antigen (HLA) and immune regulation: how do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections?. Frontiers in immunology, 8, 832.

Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H., & Alter, G. (2019, March). Sex differences in vaccine-induced humoral immunity. In Seminars in immunopathology (Vol. 41, pp. 239-249). Springer Berlin Heidelberg.

Fonseca, L. L., Joyner, C. J., MaHPIC Consortium, Galinski, M. R., & Voit, E. O. (2017). A model of Plasmodium vivax concealment based on Plasmodium cynomolgi infections in Macaca mulatta. Malaria Journal, 16, 1-11

Furman, D., & Davis, M. M. (2015). New approaches to understanding the immune response to vaccination and infection. Vaccine, 33(40), 5271-5281.

Gfeller, D., & Bassani-Sternberg, M. (2018). Predicting antigen presentation—what could we learn from a million peptides?. Frontiers in immunology, 9, 1716.

Giacomet, V., Masetti, M., Nannini, P., Forlanini, F., Clerici, M., Zuccotti, G. V., & Trabattoni, D. (2018). Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults. PloS one, 13(2), e0192638.

Hossain, M. U., Omar, T. M., Oany, A. R., Kibria, K. K., Shibly, A. Z., Moniruzzaman, M., ... & Islam, M. M. (2018). Design of peptide-based epitope vaccine and further binding site scrutiny led to groundswell in drug discovery against Lassa virus. 3 Biotech, 8, 1-14.

Kaifu, T., & Nakamura, A. (2017). Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review. International Immunology, 29(7), 319-325.

Kaliamurthi, S., Selvaraj, G., Kaushik, A. C., Gu, K. R., & Wei, D. Q. (2018). Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus. Biologics: Targets and Therapy, 107-125.

Khatoon, N., Pandey, R. K., & Prajapati, V. K. (2017). Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. Scientific reports, 7(1), 8285.

Kim, H. I., Ha, N. Y., Kim, G., Min, C. K., Kim, Y., Yen, N. T. H., ... & Cho, N. H. (2019). Immunization with a recombinant antigen composed of conserved blocks from TSA56 provides broad genotype protection against scrub typhus. Emerging Microbes & Infections, 8(1), 946-958.

Lamiable, A., Thévenet, P., Rey, J., Vavrusa, M., Derreumaux, P., & Tufféry, P. (2016). PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic acids research, 44(W1), W449-W454.

Leventhal, G. E., Hill, A. L., Nowak, M. A., & Bonhoeffer, S. (2015). Evolution and emergence of infectious diseases in theoretical and real-world networks. Nature communications, 6(1), 6101.

Lindahl, J. F., & Grace, D. (2015). The consequences of human actions on risks for infectious diseases: a review. Infection ecology & epidemiology, 5(1), 30048.

Lundegaard, C., Lund, O., Buus, S., & Nielsen, M. (2010). Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology, 130(3), 309-318.

Manzoni, C., Kia, D. A., Vandrovcova, J., Hardy, J., Wood, N. W., Lewis, P. A., & Ferrari, R. (2018). Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. Briefings in bioinformatics, 19(2), 286-302.

Miller, S. E., Bell, C. S., McClain, M. S., Cover, T. L., & Giorgio, T. D. (2016). Dynamic computational model of symptomatic bacteremia to inform bacterial separation treatment requirements. PLoS One, 11(9), e0163167.

Moise, L., Gutierrez, A., Kibria, F., Martin, R., Tassone, R., Liu, R., ... & De Groot, A. S. (2015). iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Human vaccines & immunotherapeutics, 11(9), 2312-2321.

Molineros, J. E., Looger, L. L., Kim, K., Okada, Y., Terao, C., Sun, C., ... & Nath, S. K. (2019). Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. PLoS genetics, 15(4), e1008092.

Munang'andu, H. M., Mutoloki, S., & Evensen, Ø. (2015). A review of the immunological mechanisms following mucosal vaccination of finfish. Frontiers in immunology, 6, 427.

Nii-Trebi, N. I. (2017). Emerging and neglected infectious diseases: insights, advances, and challenges. BioMed research international, 2017.

Nikolich-Žugich, J. (2018). The twilight of immunity: emerging concepts in aging of the immune system. Nature immunology, 19(1), 10-19.

Odimegwu, D. C., Onah, A. I., Ifudu, F., & Oli, A. N. (2019). Evaluation of levamisole as an adjuvant for typhoid fever vaccine formulation. PhOL, 2, 336-346.

Oli, A. N., Obialor, W. O., Ifeanyichukwu, M. O., Odimegwu, D. C., Okoyeh, J. N., Emechebe, G. O., ... & Ibeanu, G. C. (2020). Immunoinformatics and vaccine development: an overview. ImmunoTargets and therapy, 13-30.

Palm, A. K. E., & Henry, C. (2019). Remembrance of things past: long-term B cell memory after infection and vaccination. Frontiers in immunology, 10, 1787.

Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., ... & Zeng, Z. (2019). Neoantigen vaccine: an emerging tumor immunotherapy. Molecular cancer, 18(1), 1-14.

Piasecka, B., Duffy, D., Urrutia, A., Quach, H., Patin, E., Posseme, C., ... & Milieu Intérieur Consortium. (2018). Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proceedings of the National Academy of Sciences, 115(3), E488-E497.

Pritam, M., Singh, G., Swaroop, S., Singh, A. K., & Singh, S. P. (2019). Exploitation of reverse vaccinology and immunoinformatics as promising platform for genome-wide screening of new effective vaccine candidates against Plasmodium falciparum. BMC bioinformatics, 19, 219-230.

Rappuoli, R., Bottomley, M. J., D'Oro, U., Finco, O., & De Gregorio, E. (2016). Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. Journal of Experimental Medicine, 213(4), 469-481.

Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018). New vaccine technologies to combat outbreak situations. Frontiers in immunology, 9, 1963.

Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., ... & Diamond, M. S. (2017). Vaccine mediated protection against Zika virus-induced congenital disease. Cell, 170(2), 273-283.

Rizwan, M., Naz, A., Ahmad, J., Naz, K., Obaid, A., Parveen, T., ... & Ali, A. (2017). VacSol: a high throughput in silico pipeline to predict potential therapeutic targets in prokaryotic pathogens using subtractive reverse vaccinology. BMC bioinformatics, 18(1), 1-7.

Rodrigues, T. C. V., Jaiswal, A. K., de Sarom, A., de Castro Oliveira, L., Oliveira, C. J. F., Ghosh, P., ... & de Castro Soares, S. (2019). Reverse vaccinology and subtractive genomics reveal new therapeutic targets against Mycoplasma pneumoniae: a causative agent of pneumonia. Royal Society Open Science, 6(7).

Saadi, M., Karkhah, A., & Nouri, H. R. (2017). Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches. Infection, Genetics and Evolution, 51, 227-234.

Sanchez-Trincado, J. L., Gomez-Perosanz, M., & Reche, P. A. (2017). Fundamentals and methods for T-and B-cell epitope prediction. Journal of immunology research, 2017.

Sarkander, J., Hojyo, S., & Tokoyoda, K. (2016). Vaccination to gain humoral immune memory. Clinical & translational immunology, 5(12), e120.

Servín-Blanco, R., Zamora-Alvarado, R., Gevorkian, G., & Manoutcharian, K. (2016). Antigenic variability: obstacles on the road to vaccines against traditionally difficult targets. Human vaccines & immunotherapeutics, 12(10), 2640-2648.

Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. Pharmacological reviews, 66(1), 334-395.

Soria-Guerra, R. E., Nieto-Gomez, R., Govea-Alonso, D. O., & Rosales-Mendoza, S. (2015). An overview of bioinformatics tools for epitope prediction: implications on vaccine development. Journal of biomedical informatics, 53, 405-414.

Wallis, J., Shenton, D. P., & Carlisle, R. C. (2019). Novel approaches for the design, delivery and administration of vaccine technologies. Clinical & Experimental Immunology, 196(2), 189-204.

Wang, Y. (2018). Development of a human leukocyte antigen-based HIV vaccine. F1000Research, 7.

Xiang, Z., & He, Y. (2013). Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology. BMC bioinformatics, 14(4), 1-10.

Zheng, J., Lin, X., Wang, X., Zheng, L., Lan, S., Jin, S., ... & Wu, J. (2017). In silico analysis of epitope-based vaccine candidates against hepatitis B virus polymerase protein. Viruses, 9(5), 112.